On November 3, 2021 NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, reported that two abstracts have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting in Washington, D.C., being held November 10-14, 2021 (Press release, NexImmune, NOV 3, 2021, View Source [SID1234594464]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation:
Title: High throughput screening of HPV-antigen peptides and expansion of tumor-specific T cells for adoptive cell therapy of HPV-associated malignancies
Abstract Number: 97
Authors: David Langan, PhD; Jourdain Lemaster; Lauren Suarez, PhD; Pratima Kunwar, PhD; Sojung Kim, PhD; Mathias Oelke, PhD
Date & Time: Friday, November 12, 2021; Poster Hall Hours: 7 am–8:30 pm EST
Title: In vivo and in vitro characterization of AIM ACT, a novel nanoparticle-based technology, expanded MART-1 specific T cells
Abstract Number: 202
Authors: Ruipeng Wang, PhD; Lauren Suarez, PhD; Emily Lu, PhD; Pratima Kunwar, PhD; Daniel Dembrow; Sojung Kim, PhD; Mathias Oelke, PhD
Date & Time: Friday, November 12, 2021; Poster Hall Hours: 7 am–8:30 pm EST
All posters presented at the poster hall will be made available as virtual ePosters throughout the SITC (Free SITC Whitepaper) 36th Annual Meeting.